Chantilly, VA, United States
Chantilly, VA, United States

Time filter

Source Type

News Article | April 19, 2017
Site: www.businesswire.com

NASHVILLE, Tenn.--(BUSINESS WIRE)--Former Santa Rosa Consulting and InfoPartners senior executive James “Butch” Baxter has joined healthcare IT software communications firm MEDarchon, officials announced today. “ Butch’s rich background in healthcare business development – particularly within the healthcare IT management and consulting space – adds a vital and exciting dimension to our team,” says Jim Sohr, MEDarchon board chairman. “ We look forward to him leading our great bench of professionals and guiding our emerging company to the next level.” Prior to joining MEDarchon, Baxter was Senior Vice President of Franklin, Tennessee-based Santa Rosa Consulting. In 2012, Santa Rosa acquired Nashville-based InfoPartners where Baxter had enjoyed a significant career in business development and strategic management relationships. In addition to information technology, Baxter’s deep experience in healthcare includes positions in the CRO and clinical lab spaces – with ClinTrials Research, Inc. and SmithKline Beecham Clinical Laboratories, respectively – and in the managed care sector with American Medical Plan. “ Since its founding by W. Baxter Webb in 2013, MEDarchon has attracted a first-rate team of bright minds focused on developing best-in-class software to improve patient safety and communication,” says Baxter. “ Our team is driven by a desire to improve both the provider and patient experience by enhancing their communication and reducing hand-off inefficiencies. “ Bottom-line: We want to make the hospital experience a little less stressful for everyone.” Webb, MEDarchon’s founder and a board member, will assume the Chief Strategy Officer role to continue developing, facilitating and driving key strategic initiatives. MEDarchon is a next-generation healthcare communications software solution for physicians, nurses and other healthcare providers. Its signature product, QUARC, enhances paging and texting communication, workflow and patient safety for physicians, nurses and other healthcare providers. Designed by clinicians and administrators, QUARC’s functionality, usability, and big data analytics were created to prevent medical errors, improve organizational efficiency, and provide an unmatched level of security. The company is affiliated with POWERED HEALTH, a Nashville-based venture-support company majority-owned by Chairman/CEO Jim Sohr. Powered Health companies are joined by a guiding mission to provide proactive software and service solutions across the full continuum of care. We are all on a mission to change the business of healthcare through proactive cloud-based technology and enhanced service solutions. We power a positive change in interoperability, revenue, engagement, and compliance. Powered Health companies are helping hospitals and providers automate clinical and business processes that have historically been manually driven by unlocking the power of the data housed in EHRs to deliver better outcomes in patient care and patient safety at a lower cost. Together we are changing the business of healthcare.


The adoption of innovative technologies, such as Computed Tomography (CT), for COPD diagnosis is expected to drive the growth. The other new technology in acute medical management of COPD is pulse oximeter that is used for outpatient monitoring.  Airway management plays a main role in testing and management of COPD. Also, with recent technological innovations, there has been a 12.1 % increase in the use of Noninvasive Mechanical Ventilation (NIV) for management of COPD. Along with technological advancements, use of digital radiography (X-ray) and advanced portable spirometers is gaining momentum in the market. Browse full research report with TOC on "Respiratory Disease Testing/Diagnostics Market Analysis By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use (Hospitals, Physicians Clinic, Clinical Laboratories, Ambulatory Services), And Segment Forecasts, 2014 - 2025 " at: http://www.grandviewresearch.com/industry-analysis/respiratory-disease-testing-market Further key findings from the report suggest: Grand View Research has segmented the respiratory disease testing/diagnostics market by product, end-use and regions. Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


The adoption of innovative technologies, such as Computed Tomography (CT), for COPD diagnosis is expected to drive the growth. The other new technology in acute medical management of COPD is pulse oximeter that is used for outpatient monitoring.  Airway management plays a main role in testing and management of COPD. Also, with recent technological innovations, there has been a 12.1 % increase in the use of Noninvasive Mechanical Ventilation (NIV) for management of COPD. Along with technological advancements, use of digital radiography (X-ray) and advanced portable spirometers is gaining momentum in the market. Browse full research report with TOC on "Respiratory Disease Testing/Diagnostics Market Analysis By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use (Hospitals, Physicians Clinic, Clinical Laboratories, Ambulatory Services), And Segment Forecasts, 2014 - 2025 " at: http://www.grandviewresearch.com/industry-analysis/respiratory-disease-testing-market Further key findings from the report suggest: Grand View Research has segmented the respiratory disease testing/diagnostics market by product, end-use and regions. Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


News Article | May 4, 2017
Site: www.businesswire.com

BURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--LabCorp® (NYSE:LH) has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services (Providence) and Catholic Health Initiatives (CHI). PAML, based in Spokane, Washington, is one of the nation’s premier medical reference laboratories and a healthcare solutions company. With the acquisition of PAML, LabCorp assumes PAML’s ownership interests in several joint ventures: Colorado Laboratory Services (CLS), Kentucky Laboratory Services (KLS), MountainStar Clinical Laboratories (MSCL), PACLAB Network Laboratories (PACLAB) and Tri-Cities Laboratory (TCL). In addition, PAML, as a LabCorp subsidiary, has acquired assets of Alpha Medical Laboratories (Alpha), a former PAML-affiliated joint venture, from its hospital owner. “For over three decades, LabCorp has focused on comprehensive, deeply-engaged relationships with health systems and hospitals,” said David P. King, chairman and chief executive officer, LabCorp. “The acquisition of PAML furthers this strategy and aligns LabCorp with Providence and CHI, two leading, innovative health systems, and deepens our engagement and growth opportunities with a number of important community-based hospitals across multiple states.” LabCorp’s acquisition of PAML represents the first step in completing the transaction. Through 2017 and into 2018, LabCorp will acquire the ownership interests in CLS, KLS and PACLAB from their hospital co-owners. The hospital partners in MSCL and in TCL continue to evaluate future options for their interests in those joint ventures, which may include a sale to LabCorp. PAML and the joint ventures serve customers in Colorado, Idaho, Kentucky, Montana, Oregon, Utah and Washington. Operations of each joint venture, including the menu of services provided, will remain substantially the same until the joint venture transition is complete and ownership has been transferred. There will be no significant changes to operations or services at PAML until all joint venture transactions are complete. The organizations have been working together to plan and implement a smooth, thoughtful transition that maintains continuity of services for patients, hospitals, clients and clinicians, and provides access to the additional capabilities of LabCorp, including access to clinical trials and research through Covance Drug Development, enhanced IT and data analytics, standardized testing platforms and broad patient access. “PAML and its joint ventures have successfully served our communities and many others for years, and we are proud of the high-quality service they have become known for,” said Mike Butler, president of operations, Providence St. Joseph Health. “Together, LabCorp and PAML will continue and expand delivery of high-quality health care services to our patients, hospitals, clients and clinicians.” Through and after the completion of the related joint venture transactions, Providence, CHI and the hospital joint venture owners will continue to provide all existing in-patient hospital laboratory services. PAML, along with LabCorp, will continue to provide the outreach testing services and reference laboratory services currently provided by PAML and the joint ventures. LabCorp and many of the health systems and hospitals that are partnered with PAML are exploring opportunities to collaborate on projects involving LabCorp’s differentiated capabilities. “As part of our mission, CHI is focused on building healthier communities,” said Kevin Lofton, CEO, Catholic Health Initiatives. “We are confident that LabCorp, as PAML’s new owner, will serve the best interests of all who have relied on us to meet their health care needs through comprehensive, high-quality laboratory services.” “This acquisition strengthens LabCorp’s relationships with anchor health systems and expands LabCorp’s geographic presence in important existing markets, allowing LabCorp to support each health system and its existing customers with expanded offerings,” said King. “It was made possible by the mutual commitment among all the parties to provide high-quality, compassionate care, and to improve the health and lives of the patients we serve and the communities where we operate.” Providence Health & Services is committed to improving the health of the communities it serves, especially for those who are poor and vulnerable. In 2016, Providence provided nearly $1.2 billion in community benefit to help meet the needs of its communities, both today and into the future. Providence Health & Services is a part of Providence St. Joseph Health, a family of organizations that includes 50 hospitals, 829 physician clinics, senior services, supportive housing and many other health and educational services. The health system and its partners employ more than 100,000 caregivers serving communities across seven states – Alaska, California, Montana, New Mexico, Oregon, Texas and Washington. Along with Saint Joseph Health, PSJH includes: in Texas, Covenant Health and Covenant Medical Group; in California, Facey Medical Foundation, Hoag Memorial Hospital Presbyterian and St. Joseph Heritage Healthcare; and in Washington, Kadlec Regional Medical Center, Pacific Medical Centers and Swedish Health Services. Catholic Health Initiatives, a nonprofit, faith-based health system formed in 1996 through the consolidation of four Catholic health systems, expresses its mission each day by creating and nurturing healthy communities in the hundreds of sites across the nation where we provide care. The nation’s third-largest nonprofit health system, Englewood, Colorado-based CHI operates in 18 states and comprises 104 hospitals, including four academic medical centers and major teaching hospitals as well as 30 critical-access facilities; community health-services organizations; accredited nursing colleges; home-health agencies; senior living communities; and other facilities and services that span the inpatient and outpatient continuum of care. In fiscal year 2016, CHI provided more than $1.1 billion in financial assistance and community benefit – a 13% increase over the previous year – for programs and services for the poor, free clinics, education and research. Financial assistance and community benefit totaled more than $2 billion with the inclusion of the unpaid costs of Medicare. The health system, which generated operating revenues of $15.9 billion in fiscal year 2016, has total assets of approximately $22.7 billion. LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of nearly $9.5 billion for 2016 through the contributions of 52,000 employees in approximately 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com. This press release contains forward-looking statements including with respect to estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.


BURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), Providence Health & Services (Providence) and Catholic Health Initiatives (CHI), today announced that they have entered into a definitive agreement for LabCorp to acquire all of the ownership interest in Pathology Associates Medical Laboratories, LLC, (PAML), one of the nation’s premier medical reference laboratories and a healthcare solutions company jointly owned by Providence and CHI. In addition to PAML, LabCorp will also acquire PAML’s interest in the following joint ventures: Colorado Laboratory Services (CLS), Kentucky Laboratory Services (KLS), MountainStar Clinical Laboratories (MSCL), PACLAB Network Laboratories (PACLAB) and Tri-Cities Laboratory (TCL). “This signature transaction strengthens LabCorp’s relationships with anchor health systems and expands LabCorp’s geographic presence into important markets,” said David P. King, chairman and chief executive officer, LabCorp. “We have always admired the commitment of PAML, its owners and its joint venture partners to providing high-quality, community-based laboratory services. LabCorp shares that same vision and commitment, and is excited to work with these industry-leading health systems and hospitals as partners to continue to provide these services.” Headquartered in Spokane, Washington, PAML and its joint ventures provide laboratory services in California, Colorado, Idaho, Kentucky, Montana, Oregon, Utah and Washington. PAML is an industry leader in joint venture partnerships with community-based hospitals. The transactions involving PAML and the PAML-affiliated joint ventures expand LabCorp’s geographic scope in the Pacific Northwest, Midwest and South. LabCorp currently provides services to several Swedish Medical Center facilities in Seattle, a partner within the Providence system. “We are proud of the high-quality service PAML and its joint ventures have provided,” said Mike Butler, president of operations, chief executive, Providence Health & Services. “We routinely evaluate how to best deliver health care services to the communities we serve and LabCorp will continue to meet the rapidly changing needs of patients and providers.” In addition, the hospital co-owners of CLS, based in Lakewood, Colorado; KLS, based in Lexington, Kentucky; and PACLAB Network Laboratories, based in Renton, Washington; have all agreed to sell their joint venture interests to LabCorp. The hospital partners in MSCL, based in Salt Lake City, Utah, and in TCL, based in Kennewick, Washington, continue to evaluate future options for their ownership of the joint venture, which may include a sale to LabCorp. The hospital co-owner of Alpha Medical Laboratory (Alpha), a PAML-affiliated joint venture based in Coeur d’Alene, Idaho, intends to acquire PAML’s interest in Alpha; after which it will sell the joint venture assets to LabCorp upon final board approval. After the staged transactions are complete, Providence, CHI and the hospital joint venture owners will continue to provide all existing in-patient hospital laboratory services. LabCorp will then continue to provide the outreach testing services and reference laboratory services currently provided by PAML and the joint ventures that are part of the overall transactions. The transactions do not include any PAML joint venture services in California. “As part of our mission, CHI is focused on building healthier communities. This goal guides our business decisions in the constantly changing dynamics and demands of health care today,” said Kevin Lofton, CEO, Catholic Health Initiatives. “We are confident that our selection of LabCorp to be PAML’s new owner will serve the best interests of all who rely on us to meet their health care needs through comprehensive, high quality laboratory services.” The transactions are subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The parties anticipate that transaction closings will begin in 2017 and continue into 2018. There will be no changes to operations or services at PAML or the joint ventures until the applicable transaction is complete. The organizations will work together to plan and implement a smooth, thoughtful transition that maintains continuity of services for patients, hospitals, clients and clinicians while providing direct access to the additional capabilities of LabCorp. Other terms of the transactions were not disclosed and no additional information is available at this time. Providence Health & Services is committed to improving the health of the communities it serves, especially for those who are poor and vulnerable. In 2016, Providence provided nearly $1.2 billion in community benefit to help meet the needs of its communities, both today and into the future. Providence Health & Services is a part of Providence St. Joseph Health, a family of organizations that includes 50 hospitals, 829 physician clinics, senior services, supportive housing and many other health and educational services. The health system and its partners employ more than 100,000 caregivers serving communities across seven states – Alaska, California, Montana, New Mexico, Oregon, Texas and Washington. Along with Saint Joseph Health, PSJH includes: in Texas, Covenant Health and Covenant Medical Group; in California, Facey Medical Foundation, Hoag Memorial Hospital Presbyterian and St. Joseph Heritage Healthcare; and in Washington, Kadlec Regional Medical Center, Pacific Medical Centers and Swedish Health Services. Catholic Health Initiatives, a nonprofit, faith-based health system formed in 1996 through the consolidation of four Catholic health systems, expresses its mission each day by creating and nurturing healthy communities in the hundreds of sites across the nation where we provide care. The nation’s third-largest nonprofit health system, Englewood, Colorado-based CHI operates in 18 states and comprises 103 hospitals, including four academic medical centers and major teaching hospitals as well as 30 critical-access facilities; community health-services organizations; accredited nursing colleges; home-health agencies; senior living communities; and other facilities and services that span the inpatient and outpatient continuum of care. In fiscal year 2016, CHI provided more than $1.1 billion in financial assistance and community benefit – a 13% increase over the previous year -- for programs and services for the poor, free clinics, education and research. Financial assistance and community benefit totaled more than $2 billion with the inclusion of the unpaid costs of Medicare. The health system, which generated operating revenues of $15.9 billion in fiscal year 2016, has total assets of approximately $22.7 billion. Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is a world leading life sciences company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to provide better care. With net revenue in excess of $9 billion in 2016, LabCorp’s 50,000 employees serve clients in 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com. This press release contains forward-looking statements including with respect to LabCorp’s (the Company) estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect LabCorp’s operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.


News Article | February 17, 2017
Site: www.prnewswire.co.uk

Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography Mass spectrometry - our new study reveals trends, R&D progress, and predicted revenues Where is the mass spectrometry market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover how to stay ahead Our 183-page report provides 111 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing mass spectrometry market. See how to exploit the opportunities. Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market and 4 different segmentations, with 2 device types, 6 technologies and 7 applications To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com • Mass Spectrometry Market Forecasts to 2027, By Application: - Academia - Biotech and Biopharma - Agriculture - Contract Research Organisations - Hospitals/ Clinical Laboratories - Environmental Industry - Materials Industry In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 12 leading national markets: The report also includes profiles and forecasts for some of the leading companies in the mass spectrometry device market, with a focus on the mass spectrometry device segment of these companies' operations. There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market. Leading companies and the potential for market growth Overall world revenue for mass spectrometry will surpass $3.8bn in 2017, our work calculates. We predict strong revenue growth through to 2027. Market entry of continuous mass spectrometry devices and increasing prevalence of neurological conditions will increase sales to 2027. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Mass Spectrometry Market report helps you In summary, our 183-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the world mass spectrometry market and 3 different segmentations, with 2 device types, 6 product categories and 7 applications - discover the industry's prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 4 regional markets and 12 of the leading national markets - North America: US, Canada, Europe: Germany, UK, France, Italy, Spain & Rest of Europe, APAC: Japan, China, Australia & New Zealand, India, & Rest of APAC and the Rest of the World • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. Visiongain's study is for everybody needing commercial analyses for the mass spectrometry device market and leading companies. You find data, trends and predictions. Get our report today The Mass Spectrometry Market Forecast 2017-2027: Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography. Avoid missing out - get our report now. To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com  or call Tel: +44(0)-20-7336-6100 To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com


Research and Markets has announced the addition of the "Spectroscopy Equipment and Accessories - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Spectroscopy Equipment and Accessories in US$ Thousand by the following Product Segments: The report profiles 117 companies including many key and niche players such as: 1. OUTLOOK A Prelude Overview Current and Future Analysis Sustained Growth for Aftermarket Products and Services 2. MARKET OVERVIEW Government Funding and Research Activities Propel Molecular Spectroscopy Market Growing Preference for Handheld Instruments Infrared Spectroscopy - A Peek into Technology and Application Trends Raman Spectroscopy - A Review of Advanced Technologies and Applications Tip-enhanced Raman Spectroscopy (TERS) Surface-enhanced Raman Spectroscopy (SERS) Spatially Offset Raman Spectroscopy (SORS) Magnetic Photoacoustoic Raman (MPR) Raman Spectroscopy Emerges as Attractive Analytical Tool for Pharmaceutical Industry Fluorescence Spectroscopy - A Gold Standard Technology Atomic Spectroscopy - An Overview Mass Spectrometry: Technological Developments and Expanding End-Use Applications to Bolster Growth Review of Select MS Technologies The Way Ahead for FT-MS and Magnetic Sector MS Technologies Portability: A Major Driving Force for MS Systems Market Nanotube Coating to Enable Miniaturization in Mass Spectrometers High Prices of MS Systems Hold Down Sales Growth Purpose-Built Mass Spectrometers to Transform Personalized Medicine Leading End Users of Mass Spectrometry Devices A Peek into Regulatory and Competitive Landscape in MS Ion-Trap Mass Spectrometry Technology Losses Sheen Reduced Government Spending on Laboratory Testing Lack of Suitable Software and Diversity of MS Systems - A Major Challenge Smaller Clinical Laboratories Continue to Shy Away from Mass Spectrometers 3. MARKET TRENDS & ISSUES Rise in Drug Development Outsourcing to Fuel Global Spectroscopy Market Growing Significance of Miniaturization in Spectroscopy Shift of Analytical Instruments Industry to Mass Customization Improved Mobility Broadens the Role of Spectroscopy Improved Analyzer Reliability and Performance Hyphenated Technologies Exhibit Growth Spectroscopy Makes Inroads into Novel Applications Applications Extend to Defense and Civilian Areas Atomic and Molecular Spectrometers Benefit from Technological Improvements Demand for Used Spectroscopy Instruments to Grow Robustly in Future 4. COMPETITIVE LANDSCAPE Competition in the Spectrometry Market: An Insight Molecular Spectroscopy: A Highly Fragmented Market List of Leading Players in the Global Molecular Spectroscopy Market by Product Type Atomic Spectroscopy Market List of Leading Players in the Global Atomic Spectroscopy Market Mass Spectrometry Market List of Leading Players in the Global Mass Spectrometry Market 5. PRODUCT OVERVIEW Spectroscopy Spectrophotometer Fluorometer Different Types of Spectrophotometry Analysis Infrared Spectrophotometry Near-Infrared Spectrophotometry Visible Spectrophotometry Ion Mobility Spectrometry Color Spectrophotometry Near-Ultraviolet Spectrophotometry Spectrometry Spectrometers: A Broad Spectrum of Devices A. Molecular Spectroscopy - The Study of Absorption of Light by Molecules Ultraviolet/Visible (UV/VIS) Spectroscopy Raman Spectroscopy Nuclear Magnetic Resonance (NMR) Spectrometers Near Infrared (NIR) Spectroscopy Applications of Near-IR Techniques Process Analysis Applications of the NIR Spectroscopy Infrared Spectroscopy Fourier-Transform Infrared (FTIR) Spectroscopy B. Atomic Spectroscopy Arc/Spark Spectrometry ICP and ICP-MS Atomic Absorption Spectroscopy Atomic Absorption Analysis Instrumentation Atomizers Double Beam Systems Applications Trends and Future Developments X-Ray Fluorescence Spectrometers (XRF) C. Mass Spectrometry (MS) Mass Spectrometer Types of Mass Spectrometers and their Applications Liquid Chromatography-Mass Spectrometry (LC-MS) Gas Chromatography-Mass Spectrometry (GC-MS) MALDI-TOF Fluorescence Spectroscopy - An Overview Biomedical Applications of Fluorescence Spectroscopy Fluorescence Quenching Fluorescence Polarization Resonance Energy Transfer Filter Fluorimeters Spectrofluorimeters Monochromators Fluorescence-Lifetime Measurements 6. PRODUCT INNOVATIONS/INTRODUCTIONS Shimadzu Launches LCMS-8045 Mass Spectrometer in Europe JUKI Group Commercializes AY555 Spectrophotometer Avantes Launches AvaSpec-Hero Sensline Spectrometer Agilent Launches New 4210 Microwave Plasma-Atomic Emission Spectrometer Princeton Launches FERGIE Spectroscopy System Konica Minolta Introduces Automobile Specific Spectrophotometers, CM-25cG and CM-M6 Shimadzu Launches New GC-MS/MS System, GCMS-TQ8050 Datacolor Introduces Datacolor 20D for Paint Retailers StellarNet Launches Portable Research Grade Raman Spectroscopy System Jenway® Launches New Visible Scanning Spectrophotometer, 7200 IRsweep to Launch IRspectrometer Shimadzu Introduces Atomic Absorption Spectrophotometer, AA-6880F Bruker Launches timsTOF System Thermo Fisher Launches New Spectrometry Devices Techkon Launches Continuous Scanning Spectrophotometer, SpectroEdge ES7500 Sciex Introduces SCIEX QTRAP® 6500+ LC-MS/MS System StellarNet Launches RED-Wave-NIRX-SR Spectrometer Thermo Scientific Launches NanoDrop One Spectrophotometers Thermo Scientific Launches GENESYS 30 Visible-Range Spectrophotometer Thermo Scientific Launches New DXR2 Line of Raman Microscopes Bruker Launches Total Reflection X-Ray Fluorescence Spectrometer, S4 TStar Agilent Launches 5110 ICP-OES Magritek Introduces 60 MHz Benchtop NMR Spectrometers, Spinsolve 60 Thermo Scientific Launches New FT-NIR Spectrometer, Nicolet iS5N Rigaku Launches New Benchtop Variable Spot EDXRF Spectrometer, Rigaku NEX DE Advion Introduces TIDES EXPRESS Merck Introduces Spectroquant® Prove Spectrophotometers Shimadzu Introduces Inductively Coupled Plasma Mass Spectrometer, ICPMS-2030 AQULABO Group Introduces Uviline 9300 and Uviline 9600 Rigaku Launches Rigaku ZSX Primus IV StellarNet BLUE-Wave Compact Spectrometers Line SPECTRO Introduces New Line of SPECTRO XEPOS Spectrometers Thermo Fisher Introduces Thermo Scientific 253 Ultra HR-IRMS StellarNet Launches BLACK-Comet-HR Specac Introduces Pearl Liquid Analysis Accessory Agilent Introduces Agilent 5977B HES GC/MSD System in China Datacolor Introduces New Line of Color Measurement Spectrophotometers Bruker Introduces HH-LIBS Device, EOS 500 Bruker Launches 10 kHz rapifleX MALDI-TOF/TOF Mass Spectrometer Konica Minolta Introduces Auto-Scanning Spectrophotometer, FD-9 Rigaku Introduces Rigaku NANOHUNTER II TXRF Spectrometer SPECTRO Introduces New SPECTROLAB Arc/Spark Optical Emission Spectrometers SPECTRO Introduces SPECTROSCOUT X-ray Fluorescence Spectrometer Bruker Introduces S2 PUMA Shimadzu Introduces Shimadzu LCMS-8060 Triple Quadrupole Mass Spectrometer Thermo Scientific Launches Orbitrap Fusion Lumos Tribrid Mass Spectrometer Agilent Introduces Agilent 6470 Triple Quadrupole LC/MS Waters Introduces Vion IMS QTof Mass Spectrometer DeNovix Introduces DS-11 FX+ Spectrophotometer / Fluorometer Agilent Launches Agilent 6545 Q-TOF Mass Spectrometry System Implen Introduces Fourth Generation NanoPhotometer® Spectrophotometers Shimadzu Corporation Compact Monochromator System Package, SPG-120-REV JEOL Develops JPS-9030, X-ray Photoelectron Spectrometer Datacolor Introduces CHECK 3 Portable Spectrophotometer SPECTRO Launches SPECTRO xSort Handheld EDXRF Spectrometers Bruker Handheld Raman Spectrometer, BRAVO Shimadzu Launches RF-6000 Spectrofluorophotometer X-Rite Introduces X-Rite Ci7800 and X-Rite Ci7600 SPECTRO Introduces SPECTRO xSORT Line of Handheld EDXRF Spectrometers Analytik Jena Introduces New ICP-MS Products, PlasmaQuant® MS and PlasmaQuant® MS Elite Ocean Optics Introduces New Miniature Spectrometer, Flame Shimadzu Launches UV1280 UVVIS Spectrophotometer in the US SPECTRO Introduces SPECTRO ARCOS High-Resolution Spectrometer JEOL Launches JMS-T200GC High-end GC-TOFMS Thermo Scientific Launches Orbitrap Based Q Exactive Focus LC MS/MS Mass Spectrometer 7. RECENT INDUSTRY ACTIVITY Bruker Acquires Active Spectrum Inc. Wasatch Photonics Acquires Process Raman Spectroscopy Technology from Mustard Tree Instruments Shimadzu Institutes Shimadzu China Mass Spectrometry Center INSION Enters into Distribution Agreement with Digilab - The United States (75) - Canada (2) - Japan (11) - Europe (40) - France (3) - Germany (11) - The United Kingdom (18) - Italy (1) - Spain (1) - Rest of Europe (6) - Asia-Pacific (Excluding Japan) (9) - Middle East (1) For more information about this report visit http://www.researchandmarkets.com/research/gxbsmg/spectroscopy


News Article | December 7, 2016
Site: www.businesswire.com

NORWALK, Conn.--(BUSINESS WIRE)--Frontier Communications Corporation (NASDAQ:FTR) has announced its membership in the Paradigm for Parity℠ coalition and its commitment to achieving gender parity throughout Frontier’s corporate leadership structure by 2030. “At Frontier we are proud to promote diversity and inclusion throughout our organization -- from our Board of Directors to our front line,” said Kathleen Weslock, EVP and Chief People Officer of Frontier. “Partnering with Paradigm for Parity℠ is another positive way for Frontier to further strengthen its commitment to addressing gender imbalance in the workplace.” The coalition’s goals include increasing the number of women in senior operating roles, setting targets and progress reports for each company; and providing women with mentors who can help them position for long-term success in their careers. To date, companies in the coalition include Accenture, Adecco, American Electric Power, APCO Worldwide, AstraZeneca, Bank of America, Cargill, DSC Logistics, Edison International, Egon Zehnder, Farient Advisors, Frontier Communications, HealthHelp, Huffington Post, Linkage, LinkedIn, McKinsey, MetricStream, NeoGenomics Clinical Laboratories, Newmont Mining Corporation, Nordstrom, VF Corp, SAP, Spencer Stuart, TDIndustries and VOYA. Visit www.paradigm4parity.com to learn more about the Paradigm for Parity℠ coalition. About Paradigm for Parity℠ The Paradigm for Parity℠ coalition comprises CEOs, senior executives, founders, board members and business academics who are committed to achieving a new norm in corporate leadership: one in which women and men have equal power, status, and opportunity. Visit www.paradigm4parity.com for more information. About Frontier Communications Frontier Communications Corporation is a leader in providing communications services to urban, suburban, and rural communities in 29 states. Frontier offers a variety of services to residential customers over its fiber-optic and copper networks, including video, high-speed internet, advanced voice, and Frontier Secure® digital protection solutions. Frontier Business Edge™ offers communications solutions to small, medium, and enterprise businesses. More information about Frontier is available at www.frontier.com. Please note that Frontier has a new logo that is available for download at https://frontier.com/corporate/pressroom.


News Article | December 9, 2016
Site: marketersmedia.com

— The report "Coagulation/Hemostasis Analyzer Market by Product (Clinical Laboratory & PoCT Analyzers), Consumables, Test (PT, Fibrinogen, APTT, ACT, D Dimer, Platelet Function), Technology (Mechanical, Optical, Electrochemical), End User (PoCT) - Forecast to 2021” report provides a detailed overview of the major drivers, restraints, challenges, opportunities and strategies impacting the coagulation analyzer market along with the estimates and forecasts of the revenue and market share analysis. The coagulation analyzers market is projected to reach USD 4.84 Billion by 2021 from USD 2.98 Billion in 2016, at a CAGR of 10.2% from 2016 to 2021. The major factor driving the growth of this market are increasing prevalence of autoimmune diseases and increasing healthcare expenditure worldwide. The report segments this market based on product, test, technology, end-users, and regions. Among the products, the clinical laboratory analyzers are expected to account for the largest share of the market. The high growth of clinical laboratory analyzers can be attributed increasing rental agreements and increasing prevalence of blood related diseases worldwide. On the basis of type of test, the coagulation analyzers market is segmented into nine major test segments, namely, prothrombin time testing, fibrinogen testing, ACT, aPTT, d dimer testing, platelet function test, anti-factor Xa test, heparin & protamine dose response test for ACT and other coagulation tests. The prothrombin time testing is the largest test segment of this market, owing to the increasing incidence of cardiovascular and blood related diseases. Based on technology, the coagulation analyzers market is segmented into mechanical, optical, electrochemical and other technologies. The optical technology segment is expected to account for the largest share of the global coagulation analyzers market in 2016. This can be attributed to better flexibility and accuracy and greater application in coagulation analysis. Based on end-users, the coagulation analyzers market are clinical laboratories, PoC testing and others. The clinical laboratories segment is expected to account for the largest share of the global coagulation analyzers market in 2016. Rise in healthcare spending has resulted in the increasing use of coagulation analyzers market testing products in hospitals. Based on regions, the global coagulation analyzers market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as increase in aging population, and increasing diseases due to urbanization in North America. Key players in the coagulation analyzers market include are Siemens AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Sysmex Corporation (Japan), Nihon Kohden Corporation (Japan), Diagnostica Stago (France), Helena Laboratories (U.S.), Instrumentation Laboratory (U.S.), and International Technidyne Corporation (U.S.). 1. Coagulation Analyzer and Consumable Manufacturers And Suppliers 2. Clinical Laboratories 3. Hospitals 4. Pharmaceutical and biotechnology companies 5. Academic research institutes related to coagulation testing market For more information, please visit http://www.marketsandmarkets.com/pdfdownload.asp?id=197226392

Loading Clinical Laboratories collaborators
Loading Clinical Laboratories collaborators